Navigation Links
Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Date:11/25/2008

clear path for the resubmission of our NDA for NEBIDO(R), our commercial products are performing extremely well in their respective markets, our late stage development programs for octreotide and pagoclone are in full gear, and our successful $105 million financing this summer gives us a strong balance sheet.

"After receiving an Approvable letter in June from the FDA on our NDA for NEBIDO, we began planning the course toward resubmission to address FDA's concerns about the quantification of the incidence of serious cough reactions in clinical trials. The NDA contained a single, serious cough reaction in approximately 4,000 injections of NEBIDO. In September, we reached agreement with FDA that submitting additional safety data from ongoing clinical trials in Europe would be appropriate and sufficient to address their concerns. The new data include the results from approximately 10,000 additional injections in Phase IV trials conducted by our partner, Bayer Schering Pharma AG, Germany. The data from these trials has been collected and we believe that there have been no additional cases of serious cough reaction implying an incidence of approximately 1 in 14,000 injections which we believe confirms the rarity of the adverse event. We expect to re-file the NDA by the end of the first calendar quarter of 2009, and FDA will have six months to review the NDA.

"We continue to see strong performance and positive trends for VANTAS(R) (prostate cancer) and SUPPRELIN(R) LA (central precocious puberty). Sales of VANTAS units in the fourth quarter were up 70% over the fourth quarter last year, and we are encouraged by the trends in the first quarter. VANTAS is the only once-yearly treatment in the market and our sales force has done a terrific job of demonstrating the benefits of a long acting product," continued Dr. Cooper.

"Adoption of SUPPRELIN LA in the treatment of central precocious puberty continues
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
9. Indevus Announces Management Changes
10. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... This market report summarizes the ... carried out in May 2013. The full report ... the responses for each question, its segmentation and ... highlights some interesting differences, particularly between Pharma, Biotech ... were developed to estimate the in house and ...
(Date:5/24/2013)... 2013 Quincy Bioscience, a leading ... of calcium-binding proteins to support healthy living, is ... study of apoaequorin in Food and ... the British Industrial Biological Research Association. , ... potential adverse effects, if any, of apoaequorin, in ...
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... present at the Jefferies 2013 Global Healthcare Conference to ... New York. Richard Smith ... Hai Tran , Chief Financial Officer, will present ... Daylight Time.   About BioScrip BioScrip, ...
(Date:5/23/2013)... SCHOFIELD, Wis. , May 23, 2013 /PRNewswire/ ... a researcher, developer, and marketer of over-the-counter (OTC) ... re-issued its research opinion on the company based ... Highlights , Non-Prescription, All Natural Product ... Show the Product Outperforms #1 Prescription Competitor ...
Breaking Biology Technology:Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 3Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 4Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3
... /PRNewswire-Asia-FirstCall/ -- Yongye Biotechnology International, Inc. (OTC Bulletin Board: ... and distributor of nutrients for plants and animals, located ... the Company,s management will host a conference call and ... overview of the Company followed by a question and ...
... more than 40 years, marking second FDA approval ... Japan, Feb. 13 Takeda Pharmaceutical Company Limited ... Inc., announced today that the United States Food ... 40 mg and 80 mg for the chronic ...
... DNA testing technology provided by GeneSeek Inc.LINCOLN, Neb., ... will be used for medical-grade source pigs which ... Minnesota non-profit organization providing pig islet cells for ... a certified Illumina CSPro laboratory and global leader ...
Cached Biology Technology:Yongye Biotechnology to Host 'Virtual Retail Road Show' to Provide Overview of the Company in English and Mandarin 2Yongye Biotechnology to Host 'Virtual Retail Road Show' to Provide Overview of the Company in English and Mandarin 3Yongye Biotechnology to Host 'Virtual Retail Road Show' to Provide Overview of the Company in English and Mandarin 4FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout 2FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout 3FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout 4Pigs to Be Genotyped to Improve Selection and Breeding for Pancreatic Islet Cell Research 2Pigs to Be Genotyped to Improve Selection and Breeding for Pancreatic Islet Cell Research 3
(Date:5/23/2013)... surgery or harsh treatments because science fails to ... of the disease. Researchers at Case Western Reserve ... technology that allows patients to safely choose to ... take drastic measures. , The project is one ... biomedical engineering at Case Western Reserve and director ...
(Date:5/23/2013)... fastest growing open-access publishers, announces the launch of ... Biotechnology . , A broad scope journal ... Biotechnology will provide a single open-access platform ... to be disseminated and discussed. , ... an open-science and interactive web platform for the ...
(Date:5/22/2013)... conclude that the 20 percent reduction in lung ... chest X-ray (CXR) screening previously reported in the ... centers in the United States. , Philadelphia, PAPhysicians ... about the benefits and risks of LDCT lung ... New England Journal of Medicine of the ...
Breaking Biology News(10 mins):Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3Frontiers launches new open-access journal in Bioengineering and Biotechnology 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... riparian willow warblers and beaver dams once were bountiful in ... once wolves left this area, elk grew more plentiful, browsing ... beavers, and sparrows have replaced the warblers in what is ... the absence of the wolf, a top predator. That's the ...
... on the rise, there is growing interest in maintaining the ... study released this week in the on-line edition of the ... a crucial role in determining how much carbon these natural ... to provide other crucial ecosystem services such as preventing erosion. ...
... tiny flatworm best known for its extraordinary ability to regenerate ... ability of stem cells to differentiate into specialized cells. The ... protein PIWI, an important regulator of stem cells in organisms ... tissue lost to injury or shed during the body's normal ...
Cached Biology News:Wolves' top-down effect 2Seeing the forest and the trees 2Regenerating worms help elucidate stem cell biology 2Regenerating worms help elucidate stem cell biology 3Regenerating worms help elucidate stem cell biology 4
... System provides a simple, rapid and ... glutathione-S-transferase (GST) fusion proteins. Immobilized glutathione ... to isolate GST-tagged protein directly from ... either a manual (requires use of ...
... Useful for the mechanical harvesting of ... and ensures even contact with the growth ... and 75cm flasks • Individually wrapped • ... Linkage: This CLS number is a new ...
... Assay Kits are ideal for studying ... compounds using fluorescence polarization (FP) The ... glutathione transferase to the ligand binding ... and a proprietary, fluorescently-tagged progesterone ligand, ...
... base (YNB) is a base medium for preparation ... contains ammonium sulfate but does not contain amino ... available. Each pouch contains reagents to prepare ... or 1000 ml of 10X YNB for S. ...
Biology Products: